GO:0006152 purine nucleoside catabolic process

Purine nucleoside catabolic process (GO:0006152) is the set of biochemical reactions that degrade purine nucleosides, which are purine bases covalently linked to ribose or deoxyribose, into their constituent free bases and sugars. This process is fundamental to nucleotide homeostasis because it recycles and salvages purines, controls the intracellular pools of adenosine, inosine, guanosine and deoxyinosine, and determines the availability of substrates for downstream purine salvage and excretion pathways. In organisms that cannot synthesize purines de novo, such as several parasitic protozoa, the balance between purine nucleoside uptake, catabolism and salvage is a matter of survival, and the transporters and enzymes involved have been studied as antiparasitic targets. For researchers, GO:0006152 matters because it sits at the intersection of immunology, oncology, neurobiology and metabolic disease. Purine nucleoside phosphorylase (PNP), the enzyme most closely associated with this term, enforces dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity, so loss or inhibition of catabolic flux has direct immunological consequences. In cancer pharmacology, purine nucleoside analogues require specific catabolic and anabolic enzymes to be activated or degraded, and the expression of these enzymes shapes drug sensitivity. In the brain, adenosine and inosine generated or preserved by purine nucleoside metabolism act as endogenous neuroprotectants during hypoxia. More recently, autophagy has been shown to act as a brake on obesity-related fibrosis by controlling purine nucleoside signalling, connecting GO:0006152 to systemic metabolic regulation. Because the pathway is enzymatically tractable and genetically well defined, it is a productive area for CRISPR-based functional genomics. Knockout, point-mutation, knock-in and overexpression models of PNP and related enzymes allow researchers to dissect how catabolic flux controls immune cell survival, antiviral responses, tumor metabolism and neuronal resilience.

GO:0006152, purine nucleoside catabolic process, is defined in QuickGO as the chemical reactions and pathways resulting in the breakdown of a purine nucleoside, one of a family of organic molecules consisting of a purine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside). In practical terms, it covers the enzymatic cleavage of purine nucleosides such as adenosine, inosine, guanosine and deoxyinosine into free purine bases and sugar phosphates, and the subsequent metabolic handling of those products. The term is a biological process and is often studied together with purine nucleoside transport and purine salvage, because the same substrates can be either degraded or recycled depending on cellular needs.

GO:0006152 is important because purine nucleoside catabolism determines the steady-state levels of both free purine bases and intact nucleosides, and these molecules are not merely metabolic intermediates but also signalling agents and drug substrates. PNP, the central enzyme of the pathway, creates dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity, so the pathway directly controls immune homeostasis. In parasitic protozoa, purine nucleoside transporters and catabolic enzymes are essential because the parasites cannot make purines de novo, making this process a validated antiparasitic target area. In neurobiology, adenosine and inosine preserved or generated through purine nucleoside metabolism act as endogenous neuroprotectants in hypoxic brain. In metabolic disease, autophagy controls purine nucleoside signalling to brake obesity-related fibrosis, showing that this catabolic process is embedded in systemic stress responses.

The genes and proteins most directly associated with GO:0006152 include purine nucleoside phosphorylase and related enzymes, transporters and salvage factors that determine the fate of purine nucleosides.

GO:0006152 is regulated at multiple levels. Enzyme abundance and catalytic activity of PNP and related enzymes set the maximum catabolic flux, and loss-of-function states in humans demonstrate that this flux is non-redundant for immune homeostasis. Substrate availability, controlled by nucleoside transporters such as ENT1, ENT2, CNT2 and PfENT1, determines how much purine nucleoside enters the cell for catabolism or salvage. Competition with salvage enzymes such as HPRT1 and APRT routes purine bases back into nucleotide pools, so the net direction of the pathway depends on the relative expression of catabolic and salvage enzymes. At the systemic level, autophagy regulates purine nucleoside signalling in obesity-related fibrosis, indicating that catabolic flux is responsive to metabolic stress and tissue remodelling cues. In the brain, hypoxia alters adenosine and inosine levels, and these nucleosides act as endogenous neuroprotectants, so oxygen availability is an additional physiological regulator of purine nucleoside metabolism.

PNP deficiency in humans causes a severe T cell immunodeficiency, and recent work has shown that PNP enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity. This places GO:0006152 at the center of immune homeostasis: when purine nucleoside catabolism is impaired, purine nucleosides and deoxynucleosides accumulate, and the resulting metabolic stress selectively affects T cell survival and TLR7-driven responses. Researchers use PNP knockout and point-mutation models to dissect how catabolic flux controls lymphocyte development and autoreactive B cell responses.

Purine nucleoside analogues are a mainstay of therapy for hematological malignancies, and their pharmacology depends on the balance between activating kinases and catabolic enzymes. Because GO:0006152 degrades purine nucleosides, changes in catabolic enzyme expression can alter the intracellular concentration of active drug metabolites and thereby influence sensitivity or resistance. This makes the pathway a relevant context for studying drug response in leukemia and lymphoma models, and for interpreting how PNP and related enzymes shape therapeutic index.

Parasitic protozoa such as Plasmodium and trypanosomatids cannot synthesize purines de novo and depend on purine nucleoside transport and catabolism for survival. Nucleoside transporters of parasitic protozoa have been characterized as drug targets, and residues in the malaria parasite purine uptake transporter PfENT1 that are critical for transporter function have been identified. Because these pathways differ from mammalian purine nucleoside catabolism, they offer opportunities for selective antiparasitic intervention.

In hypoxic brain, purine nucleosides such as adenosine and inosine act as endogenous neuroprotectants, linking GO:0006152 to neuronal survival under low oxygen. In metabolic disease, autophagy acts as a brake on obesity-related fibrosis by controlling purine nucleoside signalling, showing that catabolic flux participates in tissue remodelling and fibrosis. These findings position purine nucleoside catabolism as a node connecting metabolic stress, inflammation and neuronal resilience.

Mass spectrometry-based metabolomics and isotope tracing are the primary methods for measuring purine nucleoside catabolic flux. By quantifying adenosine, inosine, guanosine, deoxyinosine and free purine bases, researchers can determine how genetic perturbations of PNP or transporters shift the pathway. Stable-isotope-labeled nucleosides allow flux through catabolic and salvage branches to be distinguished, which is essential for interpreting whether a gene affects breakdown or recycling.

Direct enzymatic assays measure phosphorolysis of purine nucleosides by PNP and related activities. These assays are used to validate knockout or point-mutation effects on catalytic activity and to compare substrate specificity across species, including bacterial and mammalian enzymes. Coupled assays that monitor free base or sugar phosphate formation provide quantitative readouts of catabolic capacity.

RNA-seq and proteomics reveal how expression of catabolic enzymes, transporters and salvage factors changes across cell states. Because GO:0006152 flux depends on the relative abundance of competing enzymes, transcriptomic and proteomic profiling is used to identify conditions in which catabolism is favored over salvage. These methods are also used to characterize immune and metabolic phenotypes in knockout models.

Immune assays such as T cell survival, proliferation and TLR7 reporter systems are used to test the consequences of altered purine nucleoside catabolism. In neurobiology, hypoxia models combined with adenosine and inosine measurements test whether catabolic flux modulates neuronal survival. In metabolic disease research, fibrosis models combined with autophagy perturbation are used to study purine nucleoside signalling.

Researchers studying purine nucleoside catabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolite flux, immune function or drug response, and this requires precise genetic models rather than correlative expression data. EDITGENE provides CRISPR-based knockout, point-mutation, knock-in and overexpression cell models together with library screening and bioinformatics services to support such causal studies.

GO:0006152, purine nucleoside catabolic process, is a compact but consequential metabolic pathway that controls the balance between purine nucleoside degradation and salvage. Its central enzyme PNP enforces immune checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity, while the same pathway influences purine nucleoside analogue pharmacology, parasitic purine acquisition, neuroprotection in hypoxia and autophagy-linked fibrosis. Because the pathway is genetically tractable, CRISPR-based knockout, point-mutation, knock-in and overexpression models are well suited to dissecting its causal roles in immune, metabolic and neurological disease.